LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (Nasdaq: TGTX) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired TG Therapeutics shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The investigation focuses on the October 13, 2016 press release that TG Therapeutics filed an amended protocol with the Food and Drug Administration for its leukemia drug combination, GENUINE Phase 3 Trial. The Company no longer benefits from its previously negotiated Special Protocol Assessment with the FDA.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.